Atypical signaling of metabotropic glutamate receptor 1 in human melanoma cells
- 1 November 2015
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 98 (1) , 182-189
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Targeting RAS–ERK signalling in cancer: promises and challengesNature Reviews Drug Discovery, 2014
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated MelanomaNew England Journal of Medicine, 2014
- Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomasOncogene, 2014
- Functional Effects of GRM1 Suppression in Human Melanoma CellsMolecular Cancer Research, 2012
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Overcoming metastatic melanoma with BRAF inhibitorsArchives of Pharmacal Research, 2011
- Mutant BRAF Melanomas—Dependence and ResistanceCancer Cell, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformationPigment Cell & Melanoma Research, 2008